Jupiter, FL – [October 2nd, 2024] – Myosin Therapeutics is pleased to announce the addition of three highly accomplished professionals to its team, further strengthening the company’s expertise as it prepares for upcoming clinical trials. Dr. Alfredo Quinones-Hinojosa has joined as a Scientific Advisor, while Nathalie Riebel, MBA, and Valerie Ahmuty will help oversee Clinical Operations and Regulatory Affairs.
Dr. Alfredo Quinones-Hinojosa, MD, the James C. and Sarah K. Kennedy Dean of Research at Mayo Clinic Florida, is a renowned neurosurgeon specializing in brain tumor treatment and personalized medicine. As Director of the Brain Tumor and Stem Cell Laboratory at Mayo Clinic, he also leads NIH-funded research aimed at curing brain cancer. Dr. Quinones-Hinojosa will play a key role in MT-125’s clinical development, overseeing the Phase 0 portion of the study and contributing his expertise to advancing novel treatments for glioblastoma.
Nathalie Riebel, MBA, brings over 30 years of experience in clinical operations and project management, with particular expertise in oncology. Ms. Riebel has held senior roles at companies such as PDS Biotechnology and ImClone Systems (Eli Lilly). Her expertise spans preclinical stages through NDA/BLA approvals. At Myosin, she will manage clinical operations for MT-110 and MT-125, ensuring smooth execution of the company’s clinical development strategy.
Valerie Ahmuty is a regulatory and compliance professional with more than 40 years in the biomedical industry. She has extensive knowledge of FDA regulations and has successfully authored and submitted multiple INDs and NDAs for review. Valerie will oversee Myosin’s regulatory affairs, guiding the company through the regulatory landscape as MT-110 and MT-125 progress toward clinical trials.
“We are excited to welcome Dr. Quinones-Hinojosa, Ms. Riebel, and Ms. Ahmuty to the Myosin Therapeutics team,” said Dr. Courtney Miller, CEO and co-founder of Myosin Therapeutics. “Their expertise in neurosurgery, clinical operations, and regulatory affairs is invaluable as we advance MT-110 and MT-125 through clinical trials and continue our mission to bring innovative therapies to patients with cancer and substance use disorder.”
About Myosin Therapeutics
Myosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of the Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for oncology and central nervous system indications with a platform for targeting molecular nanomotor proteins. Myosin’s lead programs for glioblastoma and stimulant use disorder target non-muscle myosin II motor proteins.
For more information, email contact@myosintherapeutics.com
